| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/03/2001 | EP1064371A2 Isolated mammalian membrane protein genes and related reagents |
| 01/03/2001 | EP1064370A2 Protein phosphatase-related molecules |
| 01/03/2001 | EP1064366A1 $i(STAPHYLOCOCCUS AUREUS) GENES AND POLYPEPTIDES |
| 01/03/2001 | EP1064364A1 The cytokine family member 2-21 |
| 01/03/2001 | EP1064363A1 Retroviral packaging cell line |
| 01/03/2001 | EP1064362A1 Nek1-related protein kinase |
| 01/03/2001 | EP1064360A2 Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics |
| 01/03/2001 | EP1064356A2 Cardiac-derived stem cells |
| 01/03/2001 | EP1064354A1 Compositions and methods for gene-based vaccines to provoke t cell responses |
| 01/03/2001 | EP1064308A1 Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses |
| 01/03/2001 | EP1064307A1 Nk cell activation inducing ligand (nail) dna and polypeptides, and use thereof |
| 01/03/2001 | EP1064306A1 $i(NEPHRIN) GENE AND PROTEIN |
| 01/03/2001 | EP1064303A1 Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| 01/03/2001 | EP1064299A1 Cyclohexapeptide wf14573 or its salt, production thereof and use thereof |
| 01/03/2001 | EP1064298A2 Inhibitors of caspases |
| 01/03/2001 | EP1064297A1 95 human secreted proteins |
| 01/03/2001 | EP1064064A1 Removal of contaminants from biological products |
| 01/03/2001 | EP1064032A2 Material composition for the formation of tissue |
| 01/03/2001 | EP1064027A1 Apo-2 ligand-anti-her-2 antibody synergism |
| 01/03/2001 | EP1064026A1 Enhancement of intracellular delivery and tissue targeting of drugs and genes |
| 01/03/2001 | EP1064021A1 Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment |
| 01/03/2001 | EP1064020A1 Methods for diagnosing and treating autoimmune disease |
| 01/03/2001 | EP1064018A2 The use of isolated domains of type iv collagen to modify cell and tissue interactions |
| 01/03/2001 | EP1064017A1 A method for the prevention of a patient's fibroproliferative vasculopathy |
| 01/03/2001 | EP1064016A2 Compositions for modulating cell differentiation comprising a lipid and a morphogen |
| 01/03/2001 | EP1064015A2 Receptor derived peptides as modulators of receptor activity |
| 01/03/2001 | EP1064014A2 Medicament for preventing or treating papilloma virus-specific tumors |
| 01/03/2001 | EP1064013A1 $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES |
| 01/03/2001 | EP1064012A1 Enhancement of the pro-fertility action of a molecule involved in sperm-egg binding |
| 01/03/2001 | EP1064011A1 Metastatin and hyaluronate binding proteins and methods of use |
| 01/03/2001 | EP1064010A1 Peptide compositions and formulations and use of same |
| 01/03/2001 | EP1064008A1 Use of at least one protein extract of the moringa genus plant seeds and corresponding cosmetic and/or pharmacological composition |
| 01/03/2001 | EP1064007A1 nrdG |
| 01/03/2001 | EP1064006A1 Treatment of ulcerative colitis with tropomyosin isoforms and monoclonal antibodies to tropomyosin isoforms |
| 01/03/2001 | EP1063977A1 Coated starch capsules and a process for producing them |
| 01/03/2001 | EP1063975A1 Crosslinkable macromers bearing initiator groups |
| 01/03/2001 | EP1063887A1 P53-dependent secretion of growth inhibitory factors |
| 01/03/2001 | EP1017716A4 Car receptors and related molecules and methods |
| 01/03/2001 | EP0902624B1 Composition and its use as a food supplement or for lowering lipids in serum |
| 01/03/2001 | EP0815126B1 Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical composition |
| 01/03/2001 | EP0807183B1 Genetic therapy of diseases caused by the immune system, said therapy using a cell-specific active substance regulated by the cell cycle |
| 01/03/2001 | CN1278921A dsRNA/dsRNA-Binding protein methods and compositions |
| 01/03/2001 | CN1278866A MPL ligand analogs |
| 01/03/2001 | CN1278865A Tumor-specific antigens, methods for their production and their use for immunization and diagnosis |
| 01/03/2001 | CN1278864A Genetically modified tumor-targeted bacteria with reduced virulence |
| 01/03/2001 | CN1278791A Process for the preparation of azacyclkylalkanoyl pseudotetrapeptides |
| 01/03/2001 | CN1278737A Method for decreasing self-association of polypeptides |
| 01/03/2001 | CN1278736A Hmanized antibodies to human gp39, compositions containing and therapeutic use thereof |
| 01/03/2001 | CN1278734A Methods and compositions for treating rheumatoid arthritis |
| 01/03/2001 | CN1278530A Novel peptide derivative |
| 01/03/2001 | CN1060178C Derivatives of structurally modified vip and pharmacetical compositions containing them for treating servual impotense of male |
| 01/02/2001 | US6169175 Dna sequence encoding a variant m2 polypeptide of influenza a having a deletion of a domain, thus causing a reduction in hydrophobicity and an increase solubility in aqueous buffers |
| 01/02/2001 | US6169167 Antibodies to ligands for HEK4 receptors |
| 01/02/2001 | US6169109 Mixing one of a novel class of psoralen photosensitizers with said solution and irradiating the mixture |
| 01/02/2001 | US6169083 Administering an l-carnosine zinc salt or l-carnosine-zinc complex; treating the side effect of cancer chemotherapy or radiotherapy |
| 01/02/2001 | US6169074 Peptide inhibitors of neurotransmitter secretion by neuronal cells |
| 01/02/2001 | US6169073 An oligopeptide or polypeptide for activating dna binding of wild-type p53 and select tumor-derived p53 mutants; use in therapy of cancer and other disorders characterized by excessive proliferation of certain cells and tissues |
| 01/02/2001 | US6169072 Cyclic adhesion inhibitors |
| 01/02/2001 | US6169071 Compounds and methods for modulating cell adhesion |
| 01/02/2001 | US6169070 Mer receptor activation by gas6 |
| 01/02/2001 | US6169069 Therapeutic/cosmetic compositions comprising CGRP antagonists for treating the eyes or eyelids |
| 01/02/2001 | US6169068 Treating lung disease or disorder by inhalating a protein |
| 01/02/2001 | US6168950 Compound 8 to 30 nucleotides in length which specifically hybridizes and inhibits gene expression of human mitogen-activated protein kinase kinase kinase 1; anticarcinogenic/antiproliferative agents |
| 01/02/2001 | US6168946 gp75 as a tumor vaccine for melanoma |
| 01/02/2001 | US6168933 Nucleotide sequences coding a transport protein; for the classification, diagnosis, prevention, and treatment of defects in cell proliferation, lipid metabolism and transport |
| 01/02/2001 | US6168923 Compositions and methods for use of IL-12 as an adjuvant |
| 01/02/2001 | US6168920 Extracellular adhesive proteins |
| 01/02/2001 | US6168793 Heat shock protein 70 preparations in vaccination against cancer and infectious disease |
| 01/02/2001 | US6168791 Antibodies that bind immunomodulators |
| 01/02/2001 | US6168790 Use of antibodies to block the effects of gram-positive bacteria and mycobacteria |
| 01/02/2001 | US6168789 Covalently modified in its catalytic center by a phe-phe-arg-chloromethylketone |
| 01/02/2001 | US6168787 Pluripotent vaccine against enveloped viruses |
| 01/02/2001 | US6168785 Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents |
| 01/02/2001 | US6168784 Block the inflammatory effects of rantes, and are useful for the treatment of asthma, allergic rhinitis, atopic dermatitis, atheroma/atherosclerosis, rheumatoid arthritis and hiv infections |
| 01/02/2001 | US6168783 Antagonists of interleukin-15 |
| 01/02/2001 | US6168778 Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes |
| 01/02/2001 | US6168587 Needleless syringe using supersonic gas flow for particle delivery |
| 01/02/2001 | US6167888 Method for inducing partial recovery of lost voluntary motor function after spinal cord injury in a mammal |
| 01/02/2001 | US6167880 Inhaled insulin dosage control delivery enhanced by controlling total inhaled volume |
| 01/02/2001 | CA2310896A1 Hcv polymerase suitable for crystal structure analysis and method for using the enzyme |
| 01/02/2001 | CA2228932C Use of plasminogen activators to stimulate local bone growth |
| 01/02/2001 | CA2187274C Treatment of partial growth hormone insensitivity syndrome |
| 01/02/2001 | CA2184696C Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic aminoacetylmercapto derivatives |
| 01/02/2001 | CA2184692C Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide disulfide derivatives |
| 01/02/2001 | CA2114156C Elucidation and synthesis of selected pentapeptides |
| 01/02/2001 | CA2113203C Human calcium channel compositions and methods |
| 01/02/2001 | CA2086918C Biologically active compounds from blue-green algae |
| 01/02/2001 | CA2064039C Treatment to reduce edema for brain and musculature injuries |
| 01/02/2001 | CA2035899C Chimeric anti-cea antibody |
| 01/02/2001 | CA2034979C Antibiotic, deoxymulundocandin, a process for its production and its useas medicament |
| 01/02/2001 | CA2025070C Recombinant aprotinin variants genetically engineered process for the microbial preparation of homgeneously processed aprotinin variants and the therapeutic use thereof |
| 01/02/2001 | CA2019218C Magnetic protein conjugates, a process for the preparation thereof and the use thereof |
| 01/02/2001 | CA1341160C Bovine granulocyte-macrophage colony stimulating factor |
| 12/30/2000 | CA2313105A1 Treatment for diabetic complications |
| 12/28/2000 | WO2000079281A1 Extracellular camp-dependent protein kinase in diagnosis, prognosis and treatment of cancer |
| 12/28/2000 | WO2000078986A1 Regulation system of expression using nuclear ppar receptors |
| 12/28/2000 | WO2000078972A2 Regulation with binding cassette transporter protein abc1 |
| 12/28/2000 | WO2000078971A2 Atp binding cassette transporter protein abc1 popypeptides |
| 12/28/2000 | WO2000078970A1 Nucleic and proteinic acids corresponding to human gene abc1 |
| 12/28/2000 | WO2000078969A1 Hiv tat peptides and multiple peptide conjugate system |